Why all the negativity already? BOCX is simply developing various applications for their RECAF technology, which is what they have told us they were going to do all along. They talked about developing a "pregnancy-like" RECAF test quite some time ago (I think it might have been during Erthang's original interview with Dr. Moro). Well, that time has now arrived. For better or worse, this kind of announcement is something that the mainstream media just might pick up on. I think that would be a good thing in the short term, as it might lift the SP up to a more appropriate level and allow BOCX to strengthen financially (with some dilution, of course).
It seems obvious to me that the work done in developing the colorimetric test can now be applied to the development of a "point-of-care" RECAF test. Why wouldn't they do this? This is a potentially fantastic development. Granted, it all comes down to how well the RECAF technology works in detecting cancer, but I'm into the stock because it sure looks like it could be effective. What I'm really interested in seeing now is some real world results from their collaboration with the Blohkin Cancer Center.
